FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Pfizer Pulls Oxbryta Sickle Cell Drug

[ Price : $8.95]

Pfizer withdraws its sickle cell disease drug Oxbryta from all approved markets after data show the overall benefit does not outwe...

Stakeholder Diversity Action Plan Comments

[ Price : $8.95]

Three stakeholder organizations make comments and suggestions for changes in an FDA draft guidance on diversity action plans to in...

Hold Lifted on Biomea Fusion Diabetes Trials

[ Price : $8.95]

FDA lifts a clinical hold on Biomea Fusions Phase 1-2 clinical trials of its investigational covalent menin inhibitor BMF-219 in T...

Conflict of Interest Seen in Kisunla Approval

[ Price : $8.95]

Investigative journalists write in BMJ about FDA advisory committee members financial conflicts of interest in the consideration o...

Bayer Files Nubeqa sNDA for Prostate Cancer

[ Price : $8.95]

Bayer submits a supplemental NDA for oral androgen receptor inhibitor Nubeqa (darolutamide), seeking approval for its use in combi...

ODAC Nixes Checkpoint Inhibitors in Gastric Cancers

[ Price : $8.95]

The FDA Oncology Drugs Advisory Committee votes not to recommend using immune checkpoint inhibitors in first-line advanced gastric...

Info Collection on Device Recall Authority

[ Price : $8.95]

Federal Register notice: FDA sends to OMB an information collection extension entitled Medical Device Recall Authority.

Merck Favezelimab/Keytruda Trial Misses Endpoint

[ Price : $8.95]

Merck says a trial assessing favezelimab and Keytruda (pembrolizumab) failed to meet its primary endpoint in patients with previou...

FDA Posts 2 FDA-483s

[ Price : $8.95]

FDA posts forms FDA-483 issued following inspections at Samsung Bioepis in Incheon, Republic of Korea, and Terumo Yamaguchi in Yam...

Democrat Lawmakers Seek Probe of Shuren Conflicts

[ Price : $8.95]

Two House Democrat lawmakers ask the HHS Office of Inspector General to investigate potential conflict-of-interest appearances rai...